Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | US

Overview

Corporate Details

ISIN(s):: US36870W1009
LEI:
Country:: United States of America
Address:: OLGETTINA, NO. 58, 20132 MILAN
Website:: https://www.genenta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Kamada Ltd. Develops specialty plasma-derived therapeutics for rare and serious conditions.	Israel	KMDA
KAMADA LTD Develops specialty plasma-derived therapeutics for rare and serious diseases.	United States of America	KMDA
KANABO GROUP PLC Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.	United Kingdom	KNB
Kancera Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.	Sweden	KAN
KANGSTEM BIOTECH CO., LTD. Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.	South Korea	217730
Karo Pharma AB Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.	Sweden	KARO
Karyopharm Therapeutics Inc. Develops novel oral cancer therapies by inhibiting nuclear export for hard-to-treat tumors.	United States of America	KPTI
KAZIA THERAPEUTICS LTD Oncology-focused drug development firm advancing anti-cancer candidates for brain cancers in trials.	United States of America	KZIA
KBIO COMPANY Inc. Using a plant-based platform to rapidly develop biologics for public health.	South Korea	038530
Keeps Biopharma Inc. Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.	South Korea	256940